e-Edition
Obituaries
In Loving Memory
Magazines
Subscribe
Login to Comment
Register
jobs
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Life
Commentary
Contact
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
54.95
-2.23 (-3.90%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
20,579,788
Open
57.40
Bid (Size)
54.97 (200)
Ask (Size)
55.00 (200)
Prev. Close
57.18
Today's Range
54.70 - 57.45
52wk Range
42.52 - 62.89
Shares Outstanding
2,222,113,553
Dividend Yield
4.59%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
↗
June 01, 2026
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.
Via
The Motley Fool
Topics
Intellectual Property
Explore the top gainers and losers within the S&P500 index in today's session.
↗
June 01, 2026
Via
Chartmill
Performance
YTD
+2.8%
+2.8%
1 Month
-4.2%
-4.2%
3 Month
-11.9%
-11.9%
6 Month
+11.7%
+11.7%
1 Year
+12.6%
+12.6%
More News
Read More
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
June 01, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
June 01, 2026
From
Bristol Myers Squibb
Via
Business Wire
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1
May 31, 2026
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
May 29, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
From
Bristol Myers Squibb
Via
Business Wire
1 Surging Stock with Promising Prospects and 2 We Ignore
May 25, 2026
Via
StockStory
Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.
↗
May 24, 2026
Via
The Motley Fool
Topics
Intellectual Property
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
May 21, 2026
From
Bristol Myers Squibb
Via
Business Wire
The Most Undervalued Healthcare Stock in the S&P 500 Right Now
↗
May 21, 2026
Via
The Motley Fool
Topics
Intellectual Property
Stocks
1 Profitable Stock to Keep an Eye On and 2 We Brush Off
May 21, 2026
Via
StockStory
Topics
Energy
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
May 20, 2026
From
Bristol Myers Squibb
Via
Business Wire
3 High-Yielding Dividend Stocks Trading at Dirt Cheap Valuations
↗
May 18, 2026
Via
The Motley Fool
10 Years Later: 5 Winners in a Thinking World
↗
May 13, 2026
Via
The Motley Fool
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
May 13, 2026
Via
StockStory
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
May 12, 2026
From
Pacira BioSciences
Via
GlobeNewswire
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
May 12, 2026
Via
StockStory
Topics
Stocks
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.
↗
May 11, 2026
Via
The Motley Fool
Topics
Intellectual Property
Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting
↗
May 10, 2026
Via
MarketBeat
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
May 08, 2026
From
Bristol Myers Squibb
Via
Business Wire
Bristol-Myers Squibb’s Q1 Earnings Call: Our Top 5 Analyst Questions
May 07, 2026
Via
StockStory
Topics
Earnings
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
May 06, 2026
From
Bristol Myers Squibb
Via
Business Wire
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
May 06, 2026
Via
StockStory
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™
May 04, 2026
From
Bristol Myers Squibb
Via
Business Wire
Frequently Asked Questions
Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 54.95
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 06/01/26 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 122.11B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 122B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
wpDiscuz
Insert